51
|
Torkashvand F, Vaziri B. Main Quality Attributes of Monoclonal Antibodies and Effect of Cell Culture Components. IRANIAN BIOMEDICAL JOURNAL 2017; 21:131-41. [PMID: 28176518 PMCID: PMC5392216 DOI: 10.18869/acadpub.ibj.21.3.131] [Citation(s) in RCA: 44] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/22/2016] [Revised: 11/05/2016] [Accepted: 11/08/2016] [Indexed: 11/09/2022]
Abstract
The culture media optimization is an inevitable part of upstream process development in therapeutic monoclonal antibodies (mAbs) production. The quality by design (QbD) approach defines the assured quality of the final product through the development stage. An important step in QbD is determination of the main quality attributes. During the media optimization, some of the main quality attributes such as glycosylation pattern, charge variants, aggregates, and low-molecular-weight species, could be significantly altered. Here, we provide an overview of how cell culture medium components affects the main quality attributes of the mAbs. Knowing the relationship between the culture media components and the main quality attributes could be successfully utilized for a rational optimization of mammalian cell culture media for industrial mAbs production.
Collapse
Affiliation(s)
| | - Behrouz Vaziri
- Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
| |
Collapse
|
52
|
Hu Z, Tang D, Misaghi S, Jiang G, Yu C, Yim M, Shaw D, Snedecor B, Laird MW, Shen A. Evaluation of heavy chain C‐terminal deletions on productivity and product quality of monoclonal antibodies in Chinese hamster ovary (CHO) cells. Biotechnol Prog 2017; 33:786-794. [DOI: 10.1002/btpr.2444] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2016] [Revised: 01/25/2017] [Indexed: 12/20/2022]
Affiliation(s)
- Zhilan Hu
- Dept. of Early Stage Cell CultureGenentech Inc1 DNA WaySouth San Francisco CA94080
| | - Danming Tang
- Dept. of Early Stage Cell CultureGenentech Inc1 DNA WaySouth San Francisco CA94080
| | - Shahram Misaghi
- Dept. of Early Stage Cell CultureGenentech Inc1 DNA WaySouth San Francisco CA94080
| | - Guoying Jiang
- Biological Technologies, Genentech Inc1 DNA WaySouth San Francisco CA94080
| | - Christopher Yu
- Protein Analytical Chemistry, Genentech Inc1 DNA WaySouth San Francisco CA94080
| | - Mandy Yim
- Dept. of Early Stage Cell CultureGenentech Inc1 DNA WaySouth San Francisco CA94080
| | - David Shaw
- Dept. of Early Stage Cell CultureGenentech Inc1 DNA WaySouth San Francisco CA94080
| | - Brad Snedecor
- Dept. of Early Stage Cell CultureGenentech Inc1 DNA WaySouth San Francisco CA94080
| | - Michael W. Laird
- Dept. of Early Stage Cell CultureGenentech Inc1 DNA WaySouth San Francisco CA94080
| | - Amy Shen
- Dept. of Early Stage Cell CultureGenentech Inc1 DNA WaySouth San Francisco CA94080
| |
Collapse
|
53
|
Park JH, Jin JH, Lim MS, An HJ, Kim JW, Lee GM. Proteomic Analysis of Host Cell Protein Dynamics in the Culture Supernatants of Antibody-Producing CHO Cells. Sci Rep 2017; 7:44246. [PMID: 28281648 PMCID: PMC5345005 DOI: 10.1038/srep44246] [Citation(s) in RCA: 44] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2016] [Accepted: 02/06/2017] [Indexed: 12/21/2022] Open
Abstract
Chinese hamster ovary (CHO) cells are the most common cell line used for the production of therapeutic proteins including monoclonal antibodies (mAbs). Host cell proteins (HCPs), secreted and released from lysed cells, accumulate extracellularly during the cultures of recombinant CHO (rCHO) cells, potentially impairing product quality. In an effort to maintain good mAb quality during the cultures, HCPs accumulated extracellularly in batch and fed-batch cultures of a mAb-producing rCHO cell line were identified and quantified by nanoflow liquid chromatography-tandem mass spectrometry, followed by their gene ontology and functional analysis. Due to higher cell concentration and longer culture duration, more HCPs were identified and quantitated in fed-batch culture (2145 proteins identified and 1673 proteins quantified) than in batch culture (1934 proteins identified and 1486 proteins quantified). Clustering analysis of HCPs showed that the concentration profiles of HCPs affecting mAb quality (Lgmn, Ctsd, Gbl1, and B4galt1) correlated with changes in mAb quality attributes such as aggregation, charge variants, and N-glycosylation during the cultures. Taken together, the dataset of HCPs obtained in this study provides insights into determining the appropriate target proteins to be removed during both the cultures and purification steps for ensuring good mAb quality.
Collapse
Affiliation(s)
- Jin Hyoung Park
- Department of Biological Sciences, KAIST, 291 Daehak-ro, Yuseong-gu, Daejeon 34141, Republic of Korea
| | - Jong Hwa Jin
- New Drug Development Center, 123 Osongsaengmyeng-ro, Cheongju-si, Chungbuk 28160, Republic of Korea
| | - Myung Sin Lim
- New Drug Development Center, 123 Osongsaengmyeng-ro, Cheongju-si, Chungbuk 28160, Republic of Korea
| | - Hyun Joo An
- Graduate School of Analytical Science &Technology, Chungnam National University, 99 Daehak-ro, Yuseong-gu, Daejon 34134, Republic of Korea
| | - Jong Won Kim
- New Drug Development Center, 123 Osongsaengmyeng-ro, Cheongju-si, Chungbuk 28160, Republic of Korea
| | - Gyun Min Lee
- Department of Biological Sciences, KAIST, 291 Daehak-ro, Yuseong-gu, Daejeon 34141, Republic of Korea
| |
Collapse
|
54
|
Charge variant analysis of proposed biosimilar to Trastuzumab. Biologicals 2017; 46:46-56. [DOI: 10.1016/j.biologicals.2016.12.006] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2016] [Revised: 11/04/2016] [Accepted: 12/20/2016] [Indexed: 12/21/2022] Open
|
55
|
Yang Y, Wang G, Song T, Lebrilla CB, Heck AJR. Resolving the micro-heterogeneity and structural integrity of monoclonal antibodies by hybrid mass spectrometric approaches. MAbs 2017; 9:638-645. [PMID: 28281873 PMCID: PMC5419080 DOI: 10.1080/19420862.2017.1290033] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
For therapeutic monoclonal antibodies (mAbs), detailed analysis of the structural integrity and heterogeneity, which results from multiple types of post-translational modifications (PTMs), is relevant to various processes, including product characterization, storage stability and quality control. Despite the recent rapid development of new bioanalytical techniques, it is still challenging to completely characterize the proteoform profile of a mAb. As a nearly indispensable tool in mAb analysis, mass spectrometry (MS) provides unique structural information at multiple levels. Here, we tested a hybrid strategy for the comprehensive characterization of micro-heterogeneity by integrating 2 state-of-the-art MS-based approaches, high-resolution native MS and targeted glycan profiling, to perform complementary analysis at the intact protein level and released glycan level, respectively. We compared the performance of these methods using samples of engineered half-body IgG4s and a panel of mAbs approved for human use. The glycosylation characterization data derived from these approaches were found to be mutually consistent in composition profiling, and complementary in identification and relative-quantitation of low-abundant uncommon glycoforms. In addition, multiple other sources of micro-heterogeneity, such as glycation, lack of glycosylation, and loss of light chains, could be detected by this approach, and the contribution of multiple types of modifications to the overall micro-heterogeneity could be assessed using our superposition algorithm. Our data demonstrate that the hybrid strategy allows reliable and thorough characterization of mAbs, revealing product characteristics that would easily be missed if only a single approach were used.
Collapse
Affiliation(s)
- Yang Yang
- a Biomolecular Mass Spectrometry and Proteomics , Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, University of Utrecht , Utrecht , The Netherlands.,b Netherlands Proteomics Center , Utrecht , The Netherlands
| | - Guanbo Wang
- a Biomolecular Mass Spectrometry and Proteomics , Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, University of Utrecht , Utrecht , The Netherlands.,b Netherlands Proteomics Center , Utrecht , The Netherlands
| | - Ting Song
- c Department of Chemistry , University of California , Davis , CA , USA
| | | | - Albert J R Heck
- a Biomolecular Mass Spectrometry and Proteomics , Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, University of Utrecht , Utrecht , The Netherlands.,b Netherlands Proteomics Center , Utrecht , The Netherlands
| |
Collapse
|
56
|
Gomez N, Ambhaikar M, Zhang L, Huang CJ, Barkhordarian H, Lull J, Gutierrez C. Analysis of Tubespins as a suitable scale-down model of bioreactors for high cell density CHO cell culture. Biotechnol Prog 2017; 33:490-499. [DOI: 10.1002/btpr.2418] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2016] [Revised: 11/16/2016] [Indexed: 12/30/2022]
Affiliation(s)
- Natalia Gomez
- Drug Substance Technologies, Amgen; One Amgen Center Drive; Thousand Oaks CA 91320-1799
| | - Malhar Ambhaikar
- Drug Substance Technologies, Amgen; One Amgen Center Drive; Thousand Oaks CA 91320-1799
| | - Li Zhang
- Drug Substance Technologies, Amgen; One Amgen Center Drive; Thousand Oaks CA 91320-1799
| | - Chung-Jr Huang
- Drug Substance Technologies, Amgen; One Amgen Center Drive; Thousand Oaks CA 91320-1799
| | - Hedieh Barkhordarian
- Drug Substance Technologies, Amgen; One Amgen Center Drive; Thousand Oaks CA 91320-1799
| | - Jonathan Lull
- Drug Substance Technologies, Amgen; One Amgen Center Drive; Thousand Oaks CA 91320-1799
| | - Chris Gutierrez
- Attribute Sciences, Amgen; One Amgen Center Drive; Thousand Oaks CA 91320-1799
| |
Collapse
|
57
|
Mitchelson FG, Mondia JP, Hughes EH. Effect of copper variation in yeast hydrolysate on C-terminal lysine levels of a monoclonal antibody. Biotechnol Prog 2017; 33:463-468. [DOI: 10.1002/btpr.2411] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2016] [Revised: 08/09/2016] [Indexed: 12/18/2022]
Affiliation(s)
| | | | - Erik H. Hughes
- Biogen Inc; 5000 Davis Drive, Research Triangle Park NC 27709
| |
Collapse
|
58
|
Otani Y, Yonezawa A, Tsuda M, Imai S, Ikemi Y, Nakagawa S, Omura T, Nakagawa T, Yano I, Matsubara K. Time-Dependent Structural Alteration of Rituximab Analyzed by LC/TOF-MS after a Systemic Administration to Rats. PLoS One 2017; 12:e0169588. [PMID: 28052138 PMCID: PMC5215255 DOI: 10.1371/journal.pone.0169588] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2016] [Accepted: 12/19/2016] [Indexed: 11/19/2022] Open
Abstract
Therapeutic monoclonal antibodies (mAbs) have heterogeneities in their structures. Multiple studies have reported that the variety of post-translational modifications could affect the pharmacokinetic profiles or pharmacological potencies of therapeutic mAbs. Taking into the account that the structural modification of mAbs would affect the efficacy, it is worth investigating the structural alteration of therapeutic mAbs in the blood and the relationship between their structures and pharmacological effects. Herein, we have developed the method to isolate rituximab from plasma in which endogenous IgGs interfere the detection of rituximab, and successfully developed the analytical method with a liquid chromatograph time-of-flight mass spectrometer to detect the structure of rituximab in plasma with errors less than 30 parts per millions. Eight types of carbohydrate chains in rituximab were detected by this method. Interestingly, time-dependent changes in carbohydrate chains such as AAF (G2F) and GnGn (G0) were observed in rats, although the amino acids were stable. Additionally, these structural changes were observed via incubation in plasma as in the rat experiment, suggesting that a certain type of enzyme in plasma caused the alterations of the carbohydrate chains. The present analytical methods could clarify the actual pharmacokinetics of therapeutic mAbs, and help to evaluate the interindividual variations in pharmacokinetics and efficacy.
Collapse
Affiliation(s)
- Yuki Otani
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
| | - Atushi Yonezawa
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
- Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan
- * E-mail:
| | - Masahiro Tsuda
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
- Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan
| | - Satoshi Imai
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
| | - Yasuaki Ikemi
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
| | - Shunsaku Nakagawa
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
| | - Tomohiro Omura
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
| | - Takayuki Nakagawa
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
| | - Ikuko Yano
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
- Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan
| | - Kazuo Matsubara
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
| |
Collapse
|
59
|
Investigation of the interactions of critical scale-up parameters (pH, pO 2 and pCO 2) on CHO batch performance and critical quality attributes. Bioprocess Biosyst Eng 2016; 40:251-263. [PMID: 27752770 PMCID: PMC5274649 DOI: 10.1007/s00449-016-1693-7] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2016] [Accepted: 10/07/2016] [Indexed: 12/20/2022]
Abstract
Understanding process parameter interactions and their effects on mammalian cell cultivations is an essential requirement for robust process scale-up. Furthermore, knowledge of the relationship between the process parameters and the product critical quality attributes (CQAs) is necessary to satisfy quality by design guidelines. So far, mainly the effect of single parameters on CQAs was investigated. Here, we present a comprehensive study to investigate the interactions of scale-up relevant parameters as pH, pO2 and pCO2 on CHO cell physiology, process performance and CQAs, which was based on design of experiments and extended product quality analytics. The study used a novel control strategy in which process parameters were decoupled from each other, and thus allowed their individual control at defined set points. Besides having identified the impact of single parameters on process performance and product quality, further significant interaction effects of process parameters on specific cell growth, specific productivity and amino acid metabolism could be derived using this method. Concerning single parameter effects, several monoclonal antibody (mAb) charge variants were affected by process pCO2 and pH. N-glycosylation analysis showed positive correlations between mAb sialylation and high pH values as well as a relationship between high mannose variants and process pH. This study additionally revealed several interaction effects as process pH and pCO2 interactions on mAb charge variants and N-glycosylation pattern. Hence, through our process control strategy and multivariate investigation, novel significant process parameter interactions and single effects were identified which have to be taken into account especially for process scale-up.
Collapse
|
60
|
Parr MK, Montacir O, Montacir H. Physicochemical characterization of biopharmaceuticals. J Pharm Biomed Anal 2016; 130:366-389. [DOI: 10.1016/j.jpba.2016.05.028] [Citation(s) in RCA: 49] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2016] [Revised: 05/16/2016] [Accepted: 05/17/2016] [Indexed: 12/26/2022]
|
61
|
Yin Y, Han G, Zhou J, Dillon M, McCarty L, Gavino L, Ellerman D, Spiess C, Sandoval W, Carter PJ. Precise quantification of mixtures of bispecific IgG produced in single host cells by liquid chromatography-Orbitrap high-resolution mass spectrometry. MAbs 2016; 8:1467-1476. [PMID: 27610742 PMCID: PMC5098441 DOI: 10.1080/19420862.2016.1232217] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Bispecific IgG are heterotetramers comprising 2 pairs of heavy and light chains. Co-expression of the 4 component chains in a single host cell typically yields the desired bispecific IgG plus up to 9 additional incorrect chain pairings. Several protein engineering strategies have been reported to facilitate the heterodimerization of antibody heavy chains or cognate pairing of antibody heavy and light chains. These technologies have been used to direct the efficient assembly of bispecific IgG in single host cells and minimize unwanted chain pairings. When purifying bispecific IgGs, the identification and quantification of low levels of closely related IgG contaminants are substantial analytical challenges. Here we have developed a robust high-throughput method for quantitative analysis of bispecific IgG preparations using novel online liquid chromatography in conjunction with an extended mass range Orbitrap-based high-resolution mass spectrometer. A mathematical method was developed to estimate the yields of the 2 isobaric species, namely the desired bispecific IgG and the light chain-scrambled IgG. The analytical methods described herein are anticipated to be broadly applicable to the development of bispecific IgG as drugs and potentially to other complex next-generation biotherapeutics.
Collapse
Affiliation(s)
- Yiyuan Yin
- a Antibody Engineering Department , Genentech, Inc. , South San Francisco , CA , USA
| | - Guanghui Han
- b Proteomics and Biologics Resources Department , Genentech, Inc. , South San Francisco , CA , USA
| | - Jianhui Zhou
- a Antibody Engineering Department , Genentech, Inc. , South San Francisco , CA , USA
| | - Michael Dillon
- a Antibody Engineering Department , Genentech, Inc. , South San Francisco , CA , USA
| | - Luke McCarty
- c Protein Chemistry and Structural Biology Department , Genentech, Inc. , South San Francisco , CA , USA
| | - Lou Gavino
- d Chromatography and Mass Spectrometry Division, Thermo Fisher Scientific , San Jose , CA , USA
| | - Diego Ellerman
- c Protein Chemistry and Structural Biology Department , Genentech, Inc. , South San Francisco , CA , USA
| | - Christoph Spiess
- a Antibody Engineering Department , Genentech, Inc. , South San Francisco , CA , USA
| | - Wendy Sandoval
- b Proteomics and Biologics Resources Department , Genentech, Inc. , South San Francisco , CA , USA
| | - Paul J Carter
- a Antibody Engineering Department , Genentech, Inc. , South San Francisco , CA , USA
| |
Collapse
|
62
|
Calow J, Behrens AJ, Mader S, Bockau U, Struwe WB, Harvey DJ, Cormann KU, Nowaczyk MM, Loser K, Schinor D, Hartmann MWW, Crispin M. Antibody production using a ciliate generates unusual antibody glycoforms displaying enhanced cell-killing activity. MAbs 2016; 8:1498-1511. [PMID: 27594301 PMCID: PMC5098438 DOI: 10.1080/19420862.2016.1228504] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Antibody glycosylation is a key parameter in the optimization of antibody therapeutics. Here, we describe the production of the anti-cancer monoclonal antibody rituximab in the unicellular ciliate, Tetrahymena thermophila. The resulting antibody demonstrated enhanced antibody-dependent cell-mediated cytotoxicity, which we attribute to unusual N-linked glycosylation. Detailed chromatographic and mass spectrometric analysis revealed afucosylated, oligomannose-type glycans, which, as a whole, displayed isomeric structures that deviate from the typical human counterparts, but whose branches were equivalent to fragments of metabolic intermediates observed in human glycoproteins. From the analysis of deposited crystal structures, we predict that the ciliate glycans adopt protein-carbohydrate interactions with the Fc domain that closely mimic those of native complex-type glycans. In addition, terminal glucose structures were identified that match biosynthetic precursors of human glycosylation. Our results suggest that ciliate-based expression systems offer a route to large-scale production of monoclonal antibodies exhibiting glycosylation that imparts enhanced cell killing activity.
Collapse
Affiliation(s)
| | - Anna-Janina Behrens
- b Oxford Glycobiology Institute, Department of Biochemistry, University of Oxford , Oxford , UK
| | | | | | - Weston B Struwe
- b Oxford Glycobiology Institute, Department of Biochemistry, University of Oxford , Oxford , UK
| | - David J Harvey
- b Oxford Glycobiology Institute, Department of Biochemistry, University of Oxford , Oxford , UK
| | - Kai U Cormann
- c Plant Biochemistry, Ruhr University Bochum , Bochum , Germany
| | - Marc M Nowaczyk
- c Plant Biochemistry, Ruhr University Bochum , Bochum , Germany
| | - Karin Loser
- d Department of Dermatology , University of Münster , Münster , Germany
| | - Daniel Schinor
- e Wessling GmbH, Pharmaanalytik Münster , Münster , Germany
| | | | - Max Crispin
- b Oxford Glycobiology Institute, Department of Biochemistry, University of Oxford , Oxford , UK
| |
Collapse
|
63
|
Kim DG, Kim HJ, Kim HJ. Effects of carboxypeptidase B treatment and elevated temperature on recombinant monoclonal antibody charge variants in cation-exchange chromatography analysis. Arch Pharm Res 2016; 39:1472-1481. [DOI: 10.1007/s12272-016-0818-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2016] [Accepted: 08/09/2016] [Indexed: 12/17/2022]
|
64
|
Singh SK, Narula G, Rathore AS. Should charge variants of monoclonal antibody therapeutics be considered critical quality attributes? Electrophoresis 2016; 37:2338-46. [DOI: 10.1002/elps.201600078] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2016] [Revised: 06/01/2016] [Accepted: 06/18/2016] [Indexed: 12/21/2022]
Affiliation(s)
- Sumit Kumar Singh
- Department of Chemical Engineering; Indian Institute of Technology Delhi; Hauz Khas New Delhi India
| | - Gunjan Narula
- Department of Chemical Engineering; Indian Institute of Technology Delhi; Hauz Khas New Delhi India
| | - Anurag S. Rathore
- Department of Chemical Engineering; Indian Institute of Technology Delhi; Hauz Khas New Delhi India
| |
Collapse
|
65
|
Liu H, Nowak C, Shao M, Ponniah G, Neill A. Impact of cell culture on recombinant monoclonal antibody product heterogeneity. Biotechnol Prog 2016; 32:1103-1112. [DOI: 10.1002/btpr.2327] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2016] [Revised: 07/19/2016] [Indexed: 12/20/2022]
Affiliation(s)
- Hongcheng Liu
- Product Characterization, Global Analytical and Pharmaceutical Development; Alexion Pharmaceuticals; CT06410 Cheshire
| | - Christine Nowak
- Product Characterization, Global Analytical and Pharmaceutical Development; Alexion Pharmaceuticals; CT06410 Cheshire
| | - Mei Shao
- Late Stage Upstream Development, Global Process Development; Alexion Pharmaceuticals; CT06410 Cheshire
| | - Gomathinayagam Ponniah
- Product Characterization, Global Analytical and Pharmaceutical Development; Alexion Pharmaceuticals; CT06410 Cheshire
| | - Alyssa Neill
- Product Characterization, Global Analytical and Pharmaceutical Development; Alexion Pharmaceuticals; CT06410 Cheshire
| |
Collapse
|
66
|
Jiang G, Yu C, Yadav DB, Hu Z, Amurao A, Duenas E, Wong M, Iverson M, Zheng K, Lam X, Chen J, Vega R, Ulufatu S, Leddy C, Davis H, Shen A, Wong PY, Harris R, Wang YJ, Li D. Evaluation of Heavy-Chain C-Terminal Deletion on Product Quality and Pharmacokinetics of Monoclonal Antibodies. J Pharm Sci 2016; 105:2066-72. [PMID: 27262204 DOI: 10.1016/j.xphs.2016.04.027] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2015] [Revised: 04/08/2016] [Accepted: 04/08/2016] [Indexed: 12/17/2022]
Abstract
Due to their potential influence on stability, pharmacokinetics, and product consistency, antibody charge variants have attracted considerable attention in the biotechnology industry. Subtle to significant differences in the level of charge variants and new charge variants under various cell culture conditions are often observed during routine manufacturing or process changes and pose a challenge when demonstrating product comparability. To explore potential solutions to control charge heterogeneity, monoclonal antibodies (mAbs) with native, wild-type C-termini, and mutants with C-terminal deletions of either lysine or lysine and glycine were constructed, expressed, purified, and characterized in vitro and in vivo. Analytical and physiological characterization demonstrated that the mAb mutants had greatly reduced levels of basic variants without decreasing antibody biologic activity, structural stability, pharmacokinetics, or subcutaneous bioavailability in rats. This study provides a possible solution to mitigate mAb heterogeneity in C-terminal processing, improve batch-to-batch consistency, and facilitate the comparability study during process changes.
Collapse
Affiliation(s)
- Guoying Jiang
- Biological Technologies, Genentech, 1 DNA Way, South San Francisco, California 94080.
| | - Christopher Yu
- Protein Analytical Chemistry, Genentech, 1 DNA Way, South San Francisco, California 94080
| | - Daniela B Yadav
- Department of Pharmacokinetic and Pharmacodynamic Sciences, Genentech, 1 DNA Way, South San Francisco, California 94080
| | - Zhilan Hu
- Early Stage Cell Culture, Genentech, 1 DNA Way, South San Francisco, California 94080
| | - Annamarie Amurao
- Purification Development, Genentech, 1 DNA Way, South San Francisco, California 94080
| | - Eileen Duenas
- Purification Development, Genentech, 1 DNA Way, South San Francisco, California 94080
| | - Marc Wong
- Purification Development, Genentech, 1 DNA Way, South San Francisco, California 94080
| | - Mark Iverson
- Purification Development, Genentech, 1 DNA Way, South San Francisco, California 94080
| | - Kai Zheng
- Late Stage Pharmaceutical and Processing Development, Genentech, 1 DNA Way, South San Francisco, California 94080
| | - Xanthe Lam
- Late Stage Pharmaceutical and Processing Development, Genentech, 1 DNA Way, South San Francisco, California 94080
| | - Jia Chen
- Protein Analytical Chemistry, Genentech, 1 DNA Way, South San Francisco, California 94080
| | - Roxanne Vega
- BioAnalytical Sciences, Genentech, 1 DNA Way, South San Francisco, California 94080
| | - Sheila Ulufatu
- BioAnalytical Sciences, Genentech, 1 DNA Way, South San Francisco, California 94080
| | - Cecilia Leddy
- BioAnalytical Sciences, Genentech, 1 DNA Way, South San Francisco, California 94080
| | - Helen Davis
- BioAnalytical Sciences, Genentech, 1 DNA Way, South San Francisco, California 94080
| | - Amy Shen
- Early Stage Cell Culture, Genentech, 1 DNA Way, South San Francisco, California 94080
| | - Pin Y Wong
- Biological Technologies, Genentech, 1 DNA Way, South San Francisco, California 94080
| | - Reed Harris
- Protein Analytical Chemistry, Genentech, 1 DNA Way, South San Francisco, California 94080
| | - Y John Wang
- Late Stage Pharmaceutical and Processing Development, Genentech, 1 DNA Way, South San Francisco, California 94080
| | - Dongwei Li
- Department of Pharmacokinetic and Pharmacodynamic Sciences, Genentech, 1 DNA Way, South San Francisco, California 94080
| |
Collapse
|
67
|
Cho IH, Lee N, Song D, Jung SY, Bou-Assaf G, Sosic Z, Zhang W, Lyubarskaya Y. Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept. MAbs 2016; 8:1136-55. [PMID: 27246928 PMCID: PMC4968139 DOI: 10.1080/19420862.2016.1193659] [Citation(s) in RCA: 65] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
A biosimilar is a biological medicinal product that is comparable to a reference medicinal product in terms of quality, safety, and efficacy. SB4 was developed as a biosimilar to Enbrel® (etanercept) and was approved as Benepali®, the first biosimilar of etanercept licensed in the European Union (EU). The quality assessment of SB4 was performed in accordance with the ICH comparability guideline and the biosimilar guidelines of the European Medicines Agency and Food and Drug Administration. Extensive structural, physicochemical, and biological testing was performed with state-of-the-art technologies during a side-by-side comparison of the products. Similarity of critical quality attributes (CQAs) was evaluated on the basis of tolerance intervals established from quality data obtained from more than 60 lots of EU-sourced and US-sourced etanercept. Additional quality assessment was focused on a detailed investigation of immunogenicity-related quality attributes, including hydrophobic variants, high-molecular-weight (HMW) species, N-glycolylneuraminic acid (NGNA), and α-1,3-galactose. This comprehensive characterization study demonstrated that SB4 is highly similar to the reference product, Enbrel®, in structural, physicochemical, and biological quality attributes. In addition, the levels of potential immunogenicity-related quality attributes of SB4 such as hydrophobic variants, HMW aggregates, and α-1,3-galactose were less than those of the reference product.
Collapse
Affiliation(s)
- Ick Hyun Cho
- a Quality Evaluation Team , Samsung Bioepis , Incheon , South Korea
| | - Nayoung Lee
- a Quality Evaluation Team , Samsung Bioepis , Incheon , South Korea
| | - Dami Song
- a Quality Evaluation Team , Samsung Bioepis , Incheon , South Korea
| | - Seong Young Jung
- a Quality Evaluation Team , Samsung Bioepis , Incheon , South Korea
| | | | | | | | | |
Collapse
|
68
|
Purdie JL, Kowle RL, Langland AL, Patel CN, Ouyang A, Olson DJ. Cell culture media impact on drug product solution stability. Biotechnol Prog 2016; 32:998-1008. [DOI: 10.1002/btpr.2289] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2016] [Revised: 04/20/2016] [Indexed: 01/03/2023]
Affiliation(s)
- Jennifer L. Purdie
- Bioproduct Research and Development, Lilly Research Laboratories, Eli Lilly and Company; Indianapolis IN 46285
| | - Ronald L. Kowle
- Bioproduct Research and Development, Lilly Research Laboratories, Eli Lilly and Company; Indianapolis IN 46285
| | - Amie L. Langland
- Bioproduct Research and Development, Lilly Research Laboratories, Eli Lilly and Company; Indianapolis IN 46285
| | - Chetan N. Patel
- Biotechnology Discovery Research, Lilly Research Laboratories, Eli Lilly and Company; Indianapolis IN 46285
| | - Anli Ouyang
- Bioproduct Research and Development, Lilly Research Laboratories, Eli Lilly and Company; Indianapolis IN 46285
| | - Donald J. Olson
- Bioproduct Research and Development, Lilly Research Laboratories, Eli Lilly and Company; Indianapolis IN 46285
| |
Collapse
|
69
|
Hu Z, Zhang H, Haley B, Macchi F, Yang F, Misaghi S, Elich J, Yang R, Tang Y, Joly JC, Snedecor BR, Shen A. Carboxypeptidase D is the only enzyme responsible for antibody C-terminal lysine cleavage in Chinese hamster ovary (CHO) cells. Biotechnol Bioeng 2016; 113:2100-6. [DOI: 10.1002/bit.25977] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2015] [Revised: 01/20/2016] [Accepted: 03/07/2016] [Indexed: 12/20/2022]
Affiliation(s)
- Zhilan Hu
- Department of Early Stage Cell Culture; Genentech Inc.; 1 DNA Way; South San Francisco California 94080
| | - Henry Zhang
- Department of Early Stage Cell Culture; Genentech Inc.; 1 DNA Way; South San Francisco California 94080
| | - Benjamin Haley
- Department of Molecular Biology; Genentech Inc.; 1 DNA Way; South San Francisco California
| | - Frank Macchi
- Department of Analytical Development and Quality Control; Genentech Inc.; 1 DNA Way; South San Francisco California
| | - Feng Yang
- Department of Analytical Development and Quality Control; Genentech Inc.; 1 DNA Way; South San Francisco California
| | - Shahram Misaghi
- Department of Early Stage Cell Culture; Genentech Inc.; 1 DNA Way; South San Francisco California 94080
| | - Joseph Elich
- Department of Early Stage Cell Culture; Genentech Inc.; 1 DNA Way; South San Francisco California 94080
| | - Renee Yang
- Department of Analytical Development and Quality Control; Genentech Inc.; 1 DNA Way; South San Francisco California
| | - Yun Tang
- Department of Analytical Development and Quality Control; Genentech Inc.; 1 DNA Way; South San Francisco California
| | - John C. Joly
- Department of Early Stage Cell Culture; Genentech Inc.; 1 DNA Way; South San Francisco California 94080
| | - Bradley R. Snedecor
- Department of Early Stage Cell Culture; Genentech Inc.; 1 DNA Way; South San Francisco California 94080
| | - Amy Shen
- Department of Early Stage Cell Culture; Genentech Inc.; 1 DNA Way; South San Francisco California 94080
| |
Collapse
|
70
|
Stasiłojć G, Österborg A, Blom AM, Okrój M. New perspectives on complement mediated immunotherapy. Cancer Treat Rev 2016; 45:68-75. [DOI: 10.1016/j.ctrv.2016.02.009] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2015] [Revised: 02/08/2016] [Accepted: 02/10/2016] [Indexed: 12/25/2022]
|
71
|
van den Bremer ETJ, Beurskens FJ, Voorhorst M, Engelberts PJ, de Jong RN, van der Boom BG, Cook EM, Lindorfer MA, Taylor RP, van Berkel PH, Parren PW. Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activation. MAbs 2016; 7:672-80. [PMID: 26037225 PMCID: PMC4622059 DOI: 10.1080/19420862.2015.1046665] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023] Open
Abstract
Human IgG is produced with C-terminal lysines that are cleaved off in circulation. The function of this modification was unknown and generally thought not to affect antibody function. We recently reported that efficient C1q binding and complement-dependent cytotoxicity (CDC) requires IgG hexamerization at the cell surface. Here we demonstrate that C-terminal lysines may interfere with this process, leading to suboptimal C1q binding and CDC of cells opsonized with C-terminal lysine-containing IgG. After we removed these lysines with a carboxypeptidase, maximal complement activation was observed. Interestingly, IgG1 mutants containing either a negative C-terminal charge or multiple positive charges lost CDC almost completely; however, CDC was fully restored by mixing C-terminal mutants of opposite charge. Our data indicate a novel post-translational control mechanism of human IgG: human IgG molecules are produced in a pro-form in which charged C-termini interfere with IgG hexamer formation, C1q binding and CDC. To allow maximal complement activation, C-terminal lysine processing is required to release the antibody's full cytotoxic potential.
Collapse
|
72
|
Yu C, Gao K, Zhu L, Wang W, Wang L, Zhang F, Liu C, Li M, Wormald MR, Rudd PM, Wang J. At least two Fc Neu5Gc residues of monoclonal antibodies are required for binding to anti-Neu5Gc antibody. Sci Rep 2016; 7:20029. [PMID: 26823113 PMCID: PMC4731815 DOI: 10.1038/srep20029] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2015] [Accepted: 12/14/2015] [Indexed: 12/15/2022] Open
Abstract
Two non-human glycan epitopes, galactose-α-1,3-galactose (α-gal) and Neu5Gc-α-2-6-galactose (Neu5Gc) have been shown to be antigenic when attached to Fab oligosaccharides of monoclonal antibodies (mAbs) , while α-gal attached to Fc glycans was not. However, the antigenicity of Neu5Gc on the Fc glycans remains unclear in the context that most mAbs carry only Fc glycans. After studying two clinical mAbs carrying significant amounts of Fc Neu5Gc, we show that their binding activity with anti-Neu5Gc antibody resided in a small subset of mAbs carrying two or more Fc Neu5Gc, while mAbs harboring only one Neu5Gc showed no reactivity. Since most Neu5Gc epitopes were distributed singly on the Fc of mAbs, our results suggest that the potential antigenicity of Fc Neu5Gc is low. Our study could be referenced in the process design and optimization of mAb production in murine myeloma cells and in the quality control of mAbs for industries and regulatory authorities.
Collapse
Affiliation(s)
- Chuanfei Yu
- National Institutes for Food and Drug Control, Beijing, China
| | - Kai Gao
- National Institutes for Food and Drug Control, Beijing, China
| | - Lei Zhu
- National Institutes for Food and Drug Control, Beijing, China.,International Joint Cancer Institute, the Second Military Medical University, Shanghai, China
| | - Wenbo Wang
- National Institutes for Food and Drug Control, Beijing, China
| | - Lan Wang
- National Institutes for Food and Drug Control, Beijing, China
| | - Feng Zhang
- National Institutes for Food and Drug Control, Beijing, China
| | - Chunyu Liu
- National Institutes for Food and Drug Control, Beijing, China
| | - Meng Li
- National Institutes for Food and Drug Control, Beijing, China
| | - Mark R Wormald
- Oxford Glycobiology Institute, Department of Biochemistry, University of Oxford, UK
| | - Pauline M Rudd
- National Institute for Bioprocessing Reseach and Training, Dublin, ROI.,Bioprocessing Technology Institute, A*Star, Singapore
| | - Junzhi Wang
- National Institutes for Food and Drug Control, Beijing, China
| |
Collapse
|
73
|
Pharmacokinetic Comparability of a Biosimilar Trastuzumab Anticipated from Its Physicochemical and Biological Characterization. BIOMED RESEARCH INTERNATIONAL 2015; 2015:874916. [PMID: 26682224 PMCID: PMC4668334 DOI: 10.1155/2015/874916] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/15/2015] [Accepted: 10/29/2015] [Indexed: 12/15/2022]
Abstract
Comparability between a biosimilar and its reference product requires the evaluation of critical quality attributes that may impact on its pharmacological response. Herein we present a physicochemical characterization of a biosimilar trastuzumab focused on the attributes related to the pharmacokinetic response. Capillary isoelectrofocusing (cIEF) and cation exchange chromatography (CEX) were used to evaluate charge heterogeneity; glycosylation profiles were assessed through hydrophilic interaction liquid chromatography (HILIC); aggregates content was evaluated through size exclusion chromatography (SEC) while binding affinity to FcRn was evaluated using isothermal titration calorimetry (ITC). The biosimilar trastuzumab and its reference product exhibited a high degree of similarity for the evaluated attributes. In regard to the pharmacokinetic parameters, randomized, double blind, and two-arm parallel and prospective study was employed after the administration of a single intravenous dose in healthy volunteers. No significant differences were found between the pharmacokinetic profiles of both products. Our results confirm that similarity of the critical quality attributes between a biosimilar product, obtained from a different manufacturing process, and the reference product resulted in comparable pharmacokinetic profiles, diminishing the uncertainty related to the biosimilar's safety and efficacy.
Collapse
|
74
|
Hifumi E, Matsumoto S, Nakashima H, Itonaga S, Arakawa M, Katayama Y, Kato R, Uda T. A novel method of preparing the monoform structure of catalytic antibody light chain. FASEB J 2015; 30:895-908. [PMID: 26527062 DOI: 10.1096/fj.15-276394] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2015] [Accepted: 10/19/2015] [Indexed: 11/11/2022]
Abstract
Along with the development of antibody drugs and catalytic antibodies, the structural diversity (heterogeneity) of antibodies has been given attention. For >20 yr, detailed studies on the subject have not been conducted, because the phenomenon presents many difficult and complex problems. Structural diversity provides some (or many) isoforms of an antibody distinguished by different charges, different molecular sizes, and modifications of amino acid residues. For practical use, the antibody and the subunits must have a defined structure. In recent work, we have found that the copper (Cu) ion plays a substantial role in solving the diversity problem. In the current study, we used several catalytic antibody light chains to examine the effect of the Cu ion. In all cases, the different electrical charges of the molecule converged to a single charge, giving 1 peak in cation-exchange chromatography, as well as a single spot in 2-dimensional gel electrophoresis. The Cu-binding site was investigated by using mutagenesis, ultraviolet-visible spectroscopy, atomic force microscope analysis, and molecular modeling, which suggested that histidine and cysteine residues close to the C-terminus are involved with the binding site. The constant region domain of the antibody light chain played an important role in the heterogeneity of the light chain. Our findings may be a significant tool for preparing a single defined, not multiple, isoform structure.
Collapse
Affiliation(s)
- Emi Hifumi
- *Research Promotion Institute and Department of Applied Chemistry, Faculty of Engineering, Oita University, Oita, Japan; Nanotechnology Laboratory, Institute of Systems, Information Technologies, and Nanotechnologies (ISIT), Fukuoka, Japan; Graduate School of System Life Science, Kyushu University, Fukuoka, Japan; Tottori College of Nursing, Tottori, Japan; and High Energy Accelerator Research Organization, Tsukuba, Japan
| | - Shingo Matsumoto
- *Research Promotion Institute and Department of Applied Chemistry, Faculty of Engineering, Oita University, Oita, Japan; Nanotechnology Laboratory, Institute of Systems, Information Technologies, and Nanotechnologies (ISIT), Fukuoka, Japan; Graduate School of System Life Science, Kyushu University, Fukuoka, Japan; Tottori College of Nursing, Tottori, Japan; and High Energy Accelerator Research Organization, Tsukuba, Japan
| | - Hiroki Nakashima
- *Research Promotion Institute and Department of Applied Chemistry, Faculty of Engineering, Oita University, Oita, Japan; Nanotechnology Laboratory, Institute of Systems, Information Technologies, and Nanotechnologies (ISIT), Fukuoka, Japan; Graduate School of System Life Science, Kyushu University, Fukuoka, Japan; Tottori College of Nursing, Tottori, Japan; and High Energy Accelerator Research Organization, Tsukuba, Japan
| | - Shogo Itonaga
- *Research Promotion Institute and Department of Applied Chemistry, Faculty of Engineering, Oita University, Oita, Japan; Nanotechnology Laboratory, Institute of Systems, Information Technologies, and Nanotechnologies (ISIT), Fukuoka, Japan; Graduate School of System Life Science, Kyushu University, Fukuoka, Japan; Tottori College of Nursing, Tottori, Japan; and High Energy Accelerator Research Organization, Tsukuba, Japan
| | - Mitsue Arakawa
- *Research Promotion Institute and Department of Applied Chemistry, Faculty of Engineering, Oita University, Oita, Japan; Nanotechnology Laboratory, Institute of Systems, Information Technologies, and Nanotechnologies (ISIT), Fukuoka, Japan; Graduate School of System Life Science, Kyushu University, Fukuoka, Japan; Tottori College of Nursing, Tottori, Japan; and High Energy Accelerator Research Organization, Tsukuba, Japan
| | - Yoshiki Katayama
- *Research Promotion Institute and Department of Applied Chemistry, Faculty of Engineering, Oita University, Oita, Japan; Nanotechnology Laboratory, Institute of Systems, Information Technologies, and Nanotechnologies (ISIT), Fukuoka, Japan; Graduate School of System Life Science, Kyushu University, Fukuoka, Japan; Tottori College of Nursing, Tottori, Japan; and High Energy Accelerator Research Organization, Tsukuba, Japan
| | - Ryuichi Kato
- *Research Promotion Institute and Department of Applied Chemistry, Faculty of Engineering, Oita University, Oita, Japan; Nanotechnology Laboratory, Institute of Systems, Information Technologies, and Nanotechnologies (ISIT), Fukuoka, Japan; Graduate School of System Life Science, Kyushu University, Fukuoka, Japan; Tottori College of Nursing, Tottori, Japan; and High Energy Accelerator Research Organization, Tsukuba, Japan
| | - Taizo Uda
- *Research Promotion Institute and Department of Applied Chemistry, Faculty of Engineering, Oita University, Oita, Japan; Nanotechnology Laboratory, Institute of Systems, Information Technologies, and Nanotechnologies (ISIT), Fukuoka, Japan; Graduate School of System Life Science, Kyushu University, Fukuoka, Japan; Tottori College of Nursing, Tottori, Japan; and High Energy Accelerator Research Organization, Tsukuba, Japan
| |
Collapse
|
75
|
Zhang X, Tang H, Sun YT, Liu X, Tan WS, Fan L. Elucidating the effects of arginine and lysine on a monoclonal antibody C-terminal lysine variation in CHO cell cultures. Appl Microbiol Biotechnol 2015; 99:6643-52. [DOI: 10.1007/s00253-015-6617-y] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2015] [Revised: 04/11/2015] [Accepted: 04/15/2015] [Indexed: 11/24/2022]
|
76
|
Brühlmann D, Jordan M, Hemberger J, Sauer M, Stettler M, Broly H. Tailoring recombinant protein quality by rational media design. Biotechnol Prog 2015; 31:615-29. [DOI: 10.1002/btpr.2089] [Citation(s) in RCA: 58] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2014] [Revised: 03/04/2015] [Indexed: 02/07/2023]
Affiliation(s)
- David Brühlmann
- Merck Serono SA, Corsier-sur-Vevey, Biotech Process Sciences, Zone Industrielle B; CH-1809 Fenil-sur-Corsier Switzerland
- Dept. of Biotechnology and Biophysics; Julius-Maximilians-Universität Würzburg, Biozentrum; Am Hubland DE-97074 Würzburg Germany
| | - Martin Jordan
- Merck Serono SA, Corsier-sur-Vevey, Biotech Process Sciences, Zone Industrielle B; CH-1809 Fenil-sur-Corsier Switzerland
| | - Jürgen Hemberger
- Inst. for Biochemical Engineering and Analytics; University of Applied Sciences Giessen; Wiesenstrasse 14, DE-35390 Giessen Germany
| | - Markus Sauer
- Dept. of Biotechnology and Biophysics; Julius-Maximilians-Universität Würzburg, Biozentrum; Am Hubland DE-97074 Würzburg Germany
| | - Matthieu Stettler
- Merck Serono SA, Corsier-sur-Vevey, Biotech Process Sciences, Zone Industrielle B; CH-1809 Fenil-sur-Corsier Switzerland
| | - Hervé Broly
- Merck Serono SA, Corsier-sur-Vevey, Biotech Process Sciences, Zone Industrielle B; CH-1809 Fenil-sur-Corsier Switzerland
| |
Collapse
|
77
|
Yoshizawa AC, Fukuyama Y, Kajihara S, Kuyama H, Tanaka K. Computational survey of sequence specificity for protein terminal tags covering nine organisms and its application to protein identification. J Proteome Res 2015; 14:756-67. [PMID: 25393771 DOI: 10.1021/pr500793h] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
In 1998, Wilkins et al. (J. Mol. Biol. 1998, 278, 599-608) reported high specificity in terminal regions (terminal tags) of 15 519 proteins from five organisms and proposed a methodology for identifying proteins by terminal tags. However, their examined sequence data were not based on complete genome sequences. Here, we examined current proteome data (217 249 entries from UniProt 2013_6 complete/reference proteome for nine organisms including human) in terms of the specificity of terminal tags and their computational annotation. One example from the results indicated that the specificity of N-terminal tags plateaued at 28% at a length of six residues for human; even when using both N- and C-terminal tags, specificity was merely 66%. In order to determine the cause of these low specificities, the annotation of proteins sharing terminal tags with other proteins was examined. The results suggested that a large majority were phylogenetically or functionally related, whereas nonrelated proteins sharing terminal tags made up less than 1% of human proteome data. On the basis of these findings, we constructed the terminal tag sequence database ProteinCarta (http://ms3d.jp/software/proteincarta/), which includes all terminal tags of proteomes from the nine organisms analyzed here, in order to confirm the specificity of terminal tags and to identify the parent protein.
Collapse
Affiliation(s)
- Akiyasu C Yoshizawa
- Koichi Tanaka Laboratory of Advanced Science and Technology, Shimadzu Corporation , Kyoto 604-8511, Japan
| | | | | | | | | |
Collapse
|
78
|
Formolo T, Ly M, Levy M, Kilpatrick L, Lute S, Phinney K, Marzilli L, Brorson K, Boyne M, Davis D, Schiel J. Determination of the NISTmAb Primary Structure. ACS SYMPOSIUM SERIES 2015. [DOI: 10.1021/bk-2015-1201.ch001] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
Affiliation(s)
- Trina Formolo
- Biomolecular Measurement Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, United States
- Mass Spectrometry and Biophysical Characterization, Analytical Research and Development, BioTherapeutics Pharmaceutical Sciences, Pfizer, Inc., Andover, Massachusetts 01810, United States
- Janssen Research and Development, LLC, Spring House, Pennsylvania 19002, United States
- Center for Drug Evaluation and Research, Office of Testing and Research, Division of Pharmaceutical Analysis, U.S. Food and Drug Administration, Saint Louis, Missouri 63110, United States
- Center for Drug Evaluation and Research, Office of Biotechnology Products, Division of Monoclonal Antibodies, U.S Food and Drug Administration, Silver Spring, Maryland 20993, United States
| | - Mellisa Ly
- Biomolecular Measurement Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, United States
- Mass Spectrometry and Biophysical Characterization, Analytical Research and Development, BioTherapeutics Pharmaceutical Sciences, Pfizer, Inc., Andover, Massachusetts 01810, United States
- Janssen Research and Development, LLC, Spring House, Pennsylvania 19002, United States
- Center for Drug Evaluation and Research, Office of Testing and Research, Division of Pharmaceutical Analysis, U.S. Food and Drug Administration, Saint Louis, Missouri 63110, United States
- Center for Drug Evaluation and Research, Office of Biotechnology Products, Division of Monoclonal Antibodies, U.S Food and Drug Administration, Silver Spring, Maryland 20993, United States
| | - Michaella Levy
- Biomolecular Measurement Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, United States
- Mass Spectrometry and Biophysical Characterization, Analytical Research and Development, BioTherapeutics Pharmaceutical Sciences, Pfizer, Inc., Andover, Massachusetts 01810, United States
- Janssen Research and Development, LLC, Spring House, Pennsylvania 19002, United States
- Center for Drug Evaluation and Research, Office of Testing and Research, Division of Pharmaceutical Analysis, U.S. Food and Drug Administration, Saint Louis, Missouri 63110, United States
- Center for Drug Evaluation and Research, Office of Biotechnology Products, Division of Monoclonal Antibodies, U.S Food and Drug Administration, Silver Spring, Maryland 20993, United States
| | - Lisa Kilpatrick
- Biomolecular Measurement Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, United States
- Mass Spectrometry and Biophysical Characterization, Analytical Research and Development, BioTherapeutics Pharmaceutical Sciences, Pfizer, Inc., Andover, Massachusetts 01810, United States
- Janssen Research and Development, LLC, Spring House, Pennsylvania 19002, United States
- Center for Drug Evaluation and Research, Office of Testing and Research, Division of Pharmaceutical Analysis, U.S. Food and Drug Administration, Saint Louis, Missouri 63110, United States
- Center for Drug Evaluation and Research, Office of Biotechnology Products, Division of Monoclonal Antibodies, U.S Food and Drug Administration, Silver Spring, Maryland 20993, United States
| | - Scott Lute
- Biomolecular Measurement Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, United States
- Mass Spectrometry and Biophysical Characterization, Analytical Research and Development, BioTherapeutics Pharmaceutical Sciences, Pfizer, Inc., Andover, Massachusetts 01810, United States
- Janssen Research and Development, LLC, Spring House, Pennsylvania 19002, United States
- Center for Drug Evaluation and Research, Office of Testing and Research, Division of Pharmaceutical Analysis, U.S. Food and Drug Administration, Saint Louis, Missouri 63110, United States
- Center for Drug Evaluation and Research, Office of Biotechnology Products, Division of Monoclonal Antibodies, U.S Food and Drug Administration, Silver Spring, Maryland 20993, United States
| | - Karen Phinney
- Biomolecular Measurement Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, United States
- Mass Spectrometry and Biophysical Characterization, Analytical Research and Development, BioTherapeutics Pharmaceutical Sciences, Pfizer, Inc., Andover, Massachusetts 01810, United States
- Janssen Research and Development, LLC, Spring House, Pennsylvania 19002, United States
- Center for Drug Evaluation and Research, Office of Testing and Research, Division of Pharmaceutical Analysis, U.S. Food and Drug Administration, Saint Louis, Missouri 63110, United States
- Center for Drug Evaluation and Research, Office of Biotechnology Products, Division of Monoclonal Antibodies, U.S Food and Drug Administration, Silver Spring, Maryland 20993, United States
| | - Lisa Marzilli
- Biomolecular Measurement Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, United States
- Mass Spectrometry and Biophysical Characterization, Analytical Research and Development, BioTherapeutics Pharmaceutical Sciences, Pfizer, Inc., Andover, Massachusetts 01810, United States
- Janssen Research and Development, LLC, Spring House, Pennsylvania 19002, United States
- Center for Drug Evaluation and Research, Office of Testing and Research, Division of Pharmaceutical Analysis, U.S. Food and Drug Administration, Saint Louis, Missouri 63110, United States
- Center for Drug Evaluation and Research, Office of Biotechnology Products, Division of Monoclonal Antibodies, U.S Food and Drug Administration, Silver Spring, Maryland 20993, United States
| | - Kurt Brorson
- Biomolecular Measurement Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, United States
- Mass Spectrometry and Biophysical Characterization, Analytical Research and Development, BioTherapeutics Pharmaceutical Sciences, Pfizer, Inc., Andover, Massachusetts 01810, United States
- Janssen Research and Development, LLC, Spring House, Pennsylvania 19002, United States
- Center for Drug Evaluation and Research, Office of Testing and Research, Division of Pharmaceutical Analysis, U.S. Food and Drug Administration, Saint Louis, Missouri 63110, United States
- Center for Drug Evaluation and Research, Office of Biotechnology Products, Division of Monoclonal Antibodies, U.S Food and Drug Administration, Silver Spring, Maryland 20993, United States
| | - Michael Boyne
- Biomolecular Measurement Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, United States
- Mass Spectrometry and Biophysical Characterization, Analytical Research and Development, BioTherapeutics Pharmaceutical Sciences, Pfizer, Inc., Andover, Massachusetts 01810, United States
- Janssen Research and Development, LLC, Spring House, Pennsylvania 19002, United States
- Center for Drug Evaluation and Research, Office of Testing and Research, Division of Pharmaceutical Analysis, U.S. Food and Drug Administration, Saint Louis, Missouri 63110, United States
- Center for Drug Evaluation and Research, Office of Biotechnology Products, Division of Monoclonal Antibodies, U.S Food and Drug Administration, Silver Spring, Maryland 20993, United States
| | - Darryl Davis
- Biomolecular Measurement Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, United States
- Mass Spectrometry and Biophysical Characterization, Analytical Research and Development, BioTherapeutics Pharmaceutical Sciences, Pfizer, Inc., Andover, Massachusetts 01810, United States
- Janssen Research and Development, LLC, Spring House, Pennsylvania 19002, United States
- Center for Drug Evaluation and Research, Office of Testing and Research, Division of Pharmaceutical Analysis, U.S. Food and Drug Administration, Saint Louis, Missouri 63110, United States
- Center for Drug Evaluation and Research, Office of Biotechnology Products, Division of Monoclonal Antibodies, U.S Food and Drug Administration, Silver Spring, Maryland 20993, United States
| | - John Schiel
- Biomolecular Measurement Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, United States
- Mass Spectrometry and Biophysical Characterization, Analytical Research and Development, BioTherapeutics Pharmaceutical Sciences, Pfizer, Inc., Andover, Massachusetts 01810, United States
- Janssen Research and Development, LLC, Spring House, Pennsylvania 19002, United States
- Center for Drug Evaluation and Research, Office of Testing and Research, Division of Pharmaceutical Analysis, U.S. Food and Drug Administration, Saint Louis, Missouri 63110, United States
- Center for Drug Evaluation and Research, Office of Biotechnology Products, Division of Monoclonal Antibodies, U.S Food and Drug Administration, Silver Spring, Maryland 20993, United States
| |
Collapse
|
79
|
Li W, Kerwin JL, Schiel J, Formolo T, Davis D, Mahan A, Benchaar SA. Structural Elucidation of Post-Translational Modifications in Monoclonal Antibodies. ACS SYMPOSIUM SERIES 2015. [DOI: 10.1021/bk-2015-1201.ch003] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Affiliation(s)
- Wenzhou Li
- Amgen Inc., Thousand Oaks, California 91320, United States
- Sanovas Inc., Sausalito, California 94965, United States
- Analytical Chemistry Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, United States
- Janssen Research and Development, LLC, Spring House, Pennsylvania 19477, United States
| | - James L. Kerwin
- Amgen Inc., Thousand Oaks, California 91320, United States
- Sanovas Inc., Sausalito, California 94965, United States
- Analytical Chemistry Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, United States
- Janssen Research and Development, LLC, Spring House, Pennsylvania 19477, United States
| | - John Schiel
- Amgen Inc., Thousand Oaks, California 91320, United States
- Sanovas Inc., Sausalito, California 94965, United States
- Analytical Chemistry Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, United States
- Janssen Research and Development, LLC, Spring House, Pennsylvania 19477, United States
| | - Trina Formolo
- Amgen Inc., Thousand Oaks, California 91320, United States
- Sanovas Inc., Sausalito, California 94965, United States
- Analytical Chemistry Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, United States
- Janssen Research and Development, LLC, Spring House, Pennsylvania 19477, United States
| | - Darryl Davis
- Amgen Inc., Thousand Oaks, California 91320, United States
- Sanovas Inc., Sausalito, California 94965, United States
- Analytical Chemistry Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, United States
- Janssen Research and Development, LLC, Spring House, Pennsylvania 19477, United States
| | - Andrew Mahan
- Amgen Inc., Thousand Oaks, California 91320, United States
- Sanovas Inc., Sausalito, California 94965, United States
- Analytical Chemistry Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, United States
- Janssen Research and Development, LLC, Spring House, Pennsylvania 19477, United States
| | - Sabrina A. Benchaar
- Amgen Inc., Thousand Oaks, California 91320, United States
- Sanovas Inc., Sausalito, California 94965, United States
- Analytical Chemistry Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, United States
- Janssen Research and Development, LLC, Spring House, Pennsylvania 19477, United States
| |
Collapse
|
80
|
Ishii Y, Imamoto Y, Yamamoto R, Tsukahara M, Wakamatsu K. Comparison of Antibody Molecules Produced from Two Cell Lines with Contrasting Productivities and Aggregate Contents. Biol Pharm Bull 2015; 38:306-16. [DOI: 10.1248/bpb.b14-00729] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Yoichi Ishii
- Graduate School of Engineering, Gunma University
- Bio-process Research and Development Laboratories, Kyowa Hakko Kirin Co., Ltd
| | - Yasufumi Imamoto
- Bio-process Research and Development Laboratories, Kyowa Hakko Kirin Co., Ltd
| | - Rie Yamamoto
- Bio-process Research and Development Laboratories, Kyowa Hakko Kirin Co., Ltd
| | | | | |
Collapse
|
81
|
Saro D, Baker A, Hepler R, Spencer S, Bruce R, LaBrenz S, Chiu M, Davis D, Lang SE. Developability Assessment of a Proposed NIST Monoclonal Antibody. ACS SYMPOSIUM SERIES 2015. [DOI: 10.1021/bk-2015-1201.ch007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- Dorina Saro
- Analytical Discovery Group, Biologics Research, Biotechnology Center of Excellence, Janssen Research & Development, LLC, Spring House, Pennsylvania 19477, United States
- Drug Product Development, Parentals and Liquids Formulation, Janssen Research & Development, LLC, Malvern, Pennsylvania 19355, United States
| | - Audrey Baker
- Analytical Discovery Group, Biologics Research, Biotechnology Center of Excellence, Janssen Research & Development, LLC, Spring House, Pennsylvania 19477, United States
- Drug Product Development, Parentals and Liquids Formulation, Janssen Research & Development, LLC, Malvern, Pennsylvania 19355, United States
| | - Robert Hepler
- Analytical Discovery Group, Biologics Research, Biotechnology Center of Excellence, Janssen Research & Development, LLC, Spring House, Pennsylvania 19477, United States
- Drug Product Development, Parentals and Liquids Formulation, Janssen Research & Development, LLC, Malvern, Pennsylvania 19355, United States
| | - Stacey Spencer
- Analytical Discovery Group, Biologics Research, Biotechnology Center of Excellence, Janssen Research & Development, LLC, Spring House, Pennsylvania 19477, United States
- Drug Product Development, Parentals and Liquids Formulation, Janssen Research & Development, LLC, Malvern, Pennsylvania 19355, United States
| | - Rick Bruce
- Analytical Discovery Group, Biologics Research, Biotechnology Center of Excellence, Janssen Research & Development, LLC, Spring House, Pennsylvania 19477, United States
- Drug Product Development, Parentals and Liquids Formulation, Janssen Research & Development, LLC, Malvern, Pennsylvania 19355, United States
| | - Steven LaBrenz
- Analytical Discovery Group, Biologics Research, Biotechnology Center of Excellence, Janssen Research & Development, LLC, Spring House, Pennsylvania 19477, United States
- Drug Product Development, Parentals and Liquids Formulation, Janssen Research & Development, LLC, Malvern, Pennsylvania 19355, United States
| | - Mark Chiu
- Analytical Discovery Group, Biologics Research, Biotechnology Center of Excellence, Janssen Research & Development, LLC, Spring House, Pennsylvania 19477, United States
- Drug Product Development, Parentals and Liquids Formulation, Janssen Research & Development, LLC, Malvern, Pennsylvania 19355, United States
| | - Darryl Davis
- Analytical Discovery Group, Biologics Research, Biotechnology Center of Excellence, Janssen Research & Development, LLC, Spring House, Pennsylvania 19477, United States
- Drug Product Development, Parentals and Liquids Formulation, Janssen Research & Development, LLC, Malvern, Pennsylvania 19355, United States
| | - Steven E. Lang
- Analytical Discovery Group, Biologics Research, Biotechnology Center of Excellence, Janssen Research & Development, LLC, Spring House, Pennsylvania 19477, United States
- Drug Product Development, Parentals and Liquids Formulation, Janssen Research & Development, LLC, Malvern, Pennsylvania 19355, United States
| |
Collapse
|
82
|
Michels DA, Ip AY, Dillon TM, Brorson K, Lute S, Chavez B, Prentice KM, Brady LJ, Miller KJ. Separation Methods and Orthogonal Techniques. ACS SYMPOSIUM SERIES 2015. [DOI: 10.1021/bk-2015-1201.ch005] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/03/2022]
Affiliation(s)
- David A. Michels
- Department of Protein Analytical Chemistry, Genentech, South San Francisco, California 94080, United States
- Department of Process and Product Development, Amgen Inc., Thousand Oaks, California 91361, United States
- Division of Monoclonal Antibodies, Office of Biotechnology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20903, United States
- Department of Process and Product Development, Amgen Inc., Seattle, Washington 98119, United States
- Global Analytical Sciences, Amgen Inc., Thousand Oaks, California 91320, United States
| | - Anna Y. Ip
- Department of Protein Analytical Chemistry, Genentech, South San Francisco, California 94080, United States
- Department of Process and Product Development, Amgen Inc., Thousand Oaks, California 91361, United States
- Division of Monoclonal Antibodies, Office of Biotechnology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20903, United States
- Department of Process and Product Development, Amgen Inc., Seattle, Washington 98119, United States
- Global Analytical Sciences, Amgen Inc., Thousand Oaks, California 91320, United States
| | - Thomas M. Dillon
- Department of Protein Analytical Chemistry, Genentech, South San Francisco, California 94080, United States
- Department of Process and Product Development, Amgen Inc., Thousand Oaks, California 91361, United States
- Division of Monoclonal Antibodies, Office of Biotechnology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20903, United States
- Department of Process and Product Development, Amgen Inc., Seattle, Washington 98119, United States
- Global Analytical Sciences, Amgen Inc., Thousand Oaks, California 91320, United States
| | - Kurt Brorson
- Department of Protein Analytical Chemistry, Genentech, South San Francisco, California 94080, United States
- Department of Process and Product Development, Amgen Inc., Thousand Oaks, California 91361, United States
- Division of Monoclonal Antibodies, Office of Biotechnology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20903, United States
- Department of Process and Product Development, Amgen Inc., Seattle, Washington 98119, United States
- Global Analytical Sciences, Amgen Inc., Thousand Oaks, California 91320, United States
| | - Scott Lute
- Department of Protein Analytical Chemistry, Genentech, South San Francisco, California 94080, United States
- Department of Process and Product Development, Amgen Inc., Thousand Oaks, California 91361, United States
- Division of Monoclonal Antibodies, Office of Biotechnology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20903, United States
- Department of Process and Product Development, Amgen Inc., Seattle, Washington 98119, United States
- Global Analytical Sciences, Amgen Inc., Thousand Oaks, California 91320, United States
| | - Brittany Chavez
- Department of Protein Analytical Chemistry, Genentech, South San Francisco, California 94080, United States
- Department of Process and Product Development, Amgen Inc., Thousand Oaks, California 91361, United States
- Division of Monoclonal Antibodies, Office of Biotechnology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20903, United States
- Department of Process and Product Development, Amgen Inc., Seattle, Washington 98119, United States
- Global Analytical Sciences, Amgen Inc., Thousand Oaks, California 91320, United States
| | - Ken M. Prentice
- Department of Protein Analytical Chemistry, Genentech, South San Francisco, California 94080, United States
- Department of Process and Product Development, Amgen Inc., Thousand Oaks, California 91361, United States
- Division of Monoclonal Antibodies, Office of Biotechnology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20903, United States
- Department of Process and Product Development, Amgen Inc., Seattle, Washington 98119, United States
- Global Analytical Sciences, Amgen Inc., Thousand Oaks, California 91320, United States
| | - Lowell J. Brady
- Department of Protein Analytical Chemistry, Genentech, South San Francisco, California 94080, United States
- Department of Process and Product Development, Amgen Inc., Thousand Oaks, California 91361, United States
- Division of Monoclonal Antibodies, Office of Biotechnology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20903, United States
- Department of Process and Product Development, Amgen Inc., Seattle, Washington 98119, United States
- Global Analytical Sciences, Amgen Inc., Thousand Oaks, California 91320, United States
| | - Karen J. Miller
- Department of Protein Analytical Chemistry, Genentech, South San Francisco, California 94080, United States
- Department of Process and Product Development, Amgen Inc., Thousand Oaks, California 91361, United States
- Division of Monoclonal Antibodies, Office of Biotechnology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20903, United States
- Department of Process and Product Development, Amgen Inc., Seattle, Washington 98119, United States
- Global Analytical Sciences, Amgen Inc., Thousand Oaks, California 91320, United States
| |
Collapse
|
83
|
Brorson K, Jia AY. Therapeutic monoclonal antibodies and consistent ends: terminal heterogeneity, detection, and impact on quality. Curr Opin Biotechnol 2014; 30:140-6. [DOI: 10.1016/j.copbio.2014.06.012] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2014] [Revised: 06/04/2014] [Accepted: 06/15/2014] [Indexed: 01/16/2023]
|
84
|
Hmiel LK, Brorson KA, Boyne MT. Post-translational structural modifications of immunoglobulin G and their effect on biological activity. Anal Bioanal Chem 2014; 407:79-94. [DOI: 10.1007/s00216-014-8108-x] [Citation(s) in RCA: 55] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2014] [Revised: 08/08/2014] [Accepted: 08/11/2014] [Indexed: 12/15/2022]
|
85
|
Cao J, Sun W, Gong F, Liu W. Charge profiling and stability testing of biosimilar by capillary isoelectric focusing. Electrophoresis 2014; 35:1461-8. [DOI: 10.1002/elps.201300471] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2013] [Revised: 02/19/2014] [Accepted: 02/24/2014] [Indexed: 02/02/2023]
Affiliation(s)
- Junzi Cao
- School of Pharmacy; Yantai University; Yantai P. R. China
| | - Wen Sun
- State Key Laboratory of Long-acting and Targeting Drug Delivery System; Luye Pharma Group Ltd; Yantai P. R. China
| | - Feifei Gong
- School of Pharmacy; Yantai University; Yantai P. R. China
| | - Wanhui Liu
- School of Pharmacy; Yantai University; Yantai P. R. China
- State Key Laboratory of Long-acting and Targeting Drug Delivery System; Luye Pharma Group Ltd; Yantai P. R. China
| |
Collapse
|
86
|
Flores-Ortiz LF, Campos-García VR, Perdomo-Abúndez FC, Pérez NO, Medina-Rivero E. PHYSICOCHEMICAL PROPERTIES OF RITUXIMAB. J LIQ CHROMATOGR R T 2014. [DOI: 10.1080/10826076.2013.794738] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Affiliation(s)
| | | | | | - Néstor O. Pérez
- a Unidad de Investigación y Desarrollo , Tenancingo , Estado de México , México
| | | |
Collapse
|
87
|
Yang JM, Ai J, Bao Y, Yuan Z, Qin Y, Xie YW, Tao D, Fu D, Peng Y. Investigation of the correlation between charge and glycosylation of IgG1 variants by liquid chromatography–mass spectrometry. Anal Biochem 2014; 448:82-91. [DOI: 10.1016/j.ab.2013.11.020] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2013] [Revised: 11/15/2013] [Accepted: 11/18/2013] [Indexed: 10/26/2022]
|
88
|
Sandra K, Vandenheede I, Sandra P. Modern chromatographic and mass spectrometric techniques for protein biopharmaceutical characterization. J Chromatogr A 2014; 1335:81-103. [DOI: 10.1016/j.chroma.2013.11.057] [Citation(s) in RCA: 97] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2013] [Revised: 11/27/2013] [Accepted: 11/29/2013] [Indexed: 10/25/2022]
|
89
|
Barton C, Spencer D, Levitskaya S, Feng J, Harris R, Schenerman MA. Heterogeneity of IgGs: Role of Production, Processing, and Storage on Structure and Function. ACS SYMPOSIUM SERIES 2014. [DOI: 10.1021/bk-2014-1176.ch003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/03/2022]
Affiliation(s)
- Chris Barton
- Analytical Biotechnology, MedImmune, Gaithersburg, Maryland 20878, United States
- Genentech, Inc., South San Francisco, California 94080, United States
| | - David Spencer
- Analytical Biotechnology, MedImmune, Gaithersburg, Maryland 20878, United States
- Genentech, Inc., South San Francisco, California 94080, United States
| | - Sophia Levitskaya
- Analytical Biotechnology, MedImmune, Gaithersburg, Maryland 20878, United States
- Genentech, Inc., South San Francisco, California 94080, United States
| | - Jinhua Feng
- Analytical Biotechnology, MedImmune, Gaithersburg, Maryland 20878, United States
- Genentech, Inc., South San Francisco, California 94080, United States
| | - Reed Harris
- Analytical Biotechnology, MedImmune, Gaithersburg, Maryland 20878, United States
- Genentech, Inc., South San Francisco, California 94080, United States
| | - Mark A. Schenerman
- Analytical Biotechnology, MedImmune, Gaithersburg, Maryland 20878, United States
- Genentech, Inc., South San Francisco, California 94080, United States
| |
Collapse
|
90
|
Zhao SS, Chen DDY. Applications of capillary electrophoresis in characterizing recombinant protein therapeutics. Electrophoresis 2013; 35:96-108. [PMID: 24123141 DOI: 10.1002/elps.201300372] [Citation(s) in RCA: 66] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2013] [Revised: 09/16/2013] [Accepted: 09/18/2013] [Indexed: 12/15/2022]
Abstract
The use of recombinant protein for therapeutic applications has increased significantly in the last three decades. The heterogeneity of these proteins, often caused by the complex biosynthesis pathways and the subsequent PTMs, poses a challenge for drug characterization to ensure its safety, quality, integrity, and efficacy. CE, with its simple instrumentation, superior separation efficiency, small sample consumption, and short analysis time, is a well-suited analytical tool for therapeutic protein characterization. Different separation modes, including CIEF, SDS-CGE, CZE, and CE-MS, provide complementary information of the proteins. The CE applications for recombinant therapeutic proteins from the year 2000 to June 2013 are reviewed and technical concerns are discussed in this article.
Collapse
Affiliation(s)
- Shuai Sherry Zhao
- Department of Chemistry, University of British Columbia, Vancouver, Canada
| | | |
Collapse
|
91
|
|
92
|
Kinoshita M, Nakatsuji Y, Suzuki S, Hayakawa T, Kakehi K. Quality assurance of monoclonal antibody pharmaceuticals based on their charge variants using microchip isoelectric focusing method. J Chromatogr A 2013; 1309:76-83. [DOI: 10.1016/j.chroma.2013.08.021] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2013] [Revised: 07/25/2013] [Accepted: 08/06/2013] [Indexed: 12/18/2022]
|
93
|
Vijayasankaran N, Varma S, Yang Y, Mun M, Arevalo S, Gawlitzek M, Swartz T, Lim A, Li F, Zhang B, Meier S, Kiss R. Effect of cell culture medium components on color of formulated monoclonal antibody drug substance. Biotechnol Prog 2013; 29:1270-7. [PMID: 23804462 DOI: 10.1002/btpr.1772] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2013] [Revised: 05/29/2013] [Indexed: 12/16/2022]
Abstract
As the industry moves toward subcutaneous delivery as a preferred route of drug administration, high drug substance concentrations are becoming the norm for monoclonal antibodies. At such high concentrations, the drug substance may display a more intense color than at the historically lower concentrations. The effect of process conditions and/or changes on color is more readily observed in the higher color, high concentration formulations. Since color is a product quality attribute that needs to be controlled, it is useful to study the impact of process conditions and/or modifications on color. This manuscript summarizes cell culture experiments and reports on findings regarding the effect of various media components that contribute to drug substance color for a specific monoclonal antibody. In this work, lower drug substance color was achieved via optimization of the cell culture medium. Specifically, lowering the concentrations of B-vitamins in the cell culture medium has the effect of reducing color intensity by as much as 25%. In addition, decreasing concentration of iron was also directly correlated color intensity decrease of as much as 37%. It was also shown that the color of the drug substance directly correlates with increased acidic variants, especially when increased iron levels cause increased color. Potential mechanisms that could lead to antibody coloration are briefly discussed.
Collapse
|
94
|
Woods RJ, Xie MH, Von Kreudenstein TS, Ng GYK, Dixit SB. LC-MS characterization and purity assessment of a prototype bispecific antibody. MAbs 2013; 5:711-22. [PMID: 23884083 PMCID: PMC3851224 DOI: 10.4161/mabs.25488] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Bispecific IgG asymmetric (heterodimeric) antibodies offer enhanced therapeutic efficacy, but present unique challenges for drug development. These challenges are related to the proper assembly of heavy and light chains. Impurities such as symmetric (homodimeric) antibodies can arise with improper assembly. A new method to assess heterodimer purity of such bispecific antibody products is needed because traditional separation-based purity assays are unable to separate or quantify homodimer impurities. This paper presents a liquid chromatography-mass spectrometry (LC-MS)-based method for evaluating heterodimeric purity of a prototype asymmetric antibody containing two different heavy chains and two identical light chains. The heterodimer and independently expressed homodimeric standards were characterized by two complementary LC-MS techniques: Intact protein mass measurement of deglycosylated antibody and peptide map analyses. Intact protein mass analysis was used to check molecular integrity and composition. LC-MSE peptide mapping of Lys-C digests was used to verify protein sequences and characterize post-translational modifications, including C-terminal truncation species. Guided by the characterization results, a heterodimer purity assay was demonstrated by intact protein mass analysis of pure deglycosylated heterodimer spiked with each deglycosylated homodimeric standard. The assay was capable of detecting low levels (2%) of spiked homodimers in conjunction with co-eluting half antibodies and multiple mass species present in the homodimer standards and providing relative purity differences between samples. Detection of minor homodimer and half-antibody C-terminal truncation species at levels as low as 0.6% demonstrates the sensitivity of the method. This method is suitable for purity assessment of heterodimer samples during process and purification development of bispecific antibodies, e.g., clone selection.
Collapse
|
95
|
Gramer MJ. Product Quality Considerations for Mammalian Cell Culture Process Development and Manufacturing. ADVANCES IN BIOCHEMICAL ENGINEERING/BIOTECHNOLOGY 2013; 139:123-66. [DOI: 10.1007/10_2013_214] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|
96
|
Tang L, Sundaram S, Zhang J, Carlson P, Matathia A, Parekh B, Zhou Q, Hsieh MC. Conformational characterization of the charge variants of a human IgG1 monoclonal antibody using H/D exchange mass spectrometry. MAbs 2012; 5:114-25. [PMID: 23222183 DOI: 10.4161/mabs.22695] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
MAb1, a human IgG1 monoclonal antibody produced in a NS0 cell line, exhibits charge heterogeneity because of the presence of variants formed by processes such as N-terminal glutamate cyclization, C-terminal lysine truncation, deamidation, aspartate isomerization and sialylation in the carbohydrate moiety. Four major charge variants of MAb1 were isolated and the conformations of these charge variants were studied using hydrogen/deuterium exchange mass spectrometry, including the H/D exchange time course (HX-MS) and the stability of unpurified proteins from rates of H/D exchange (SUPREX) techniques. HX-MS was used to evaluate the conformation and solution dynamics of MAb1 charge variants by measuring their deuterium buildup over time at the peptide level. The SUPREX technique evaluated the unfolding profile and relative stability of the charge variants by measuring the exchange properties of globally protected amide protons in the presence of a chemical denaturant. The H/D exchange profiles from both techniques were compared among the four charge variants of MAb1. The two techniques together offered extensive understanding about the local and subglobal/global unfolding of the charge variants of MAb1. Our results demonstrated that all four charge variants of MAb1 were not significantly different in conformation, solution dynamics and chemical denaturant-induced unfolding profile and stability, which aids in understanding the biofunctions of the molecules. The analytical strategy used for conformational characterization may also be applicable to comparability studies done for antibody therapeutics.
Collapse
Affiliation(s)
- Liangjie Tang
- BioAnalytical Sciences, ImClone Systems Corporation, Wholly-Owned Subsidiary of Eli Lilly and Company, Branchburg, NJ, USA
| | | | | | | | | | | | | | | |
Collapse
|
97
|
Shi Y, Li Z, Qiao Y, Lin J. Development and validation of a rapid capillary zone electrophoresis method for determining charge variants of mAb. J Chromatogr B Analyt Technol Biomed Life Sci 2012; 906:63-8. [DOI: 10.1016/j.jchromb.2012.08.022] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2011] [Revised: 08/14/2012] [Accepted: 08/16/2012] [Indexed: 10/28/2022]
|
98
|
Du Y, Walsh A, Ehrick R, Xu W, May K, Liu H. Chromatographic analysis of the acidic and basic species of recombinant monoclonal antibodies. MAbs 2012; 4:578-85. [PMID: 22820257 DOI: 10.4161/mabs.21328] [Citation(s) in RCA: 207] [Impact Index Per Article: 17.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
The existence of multiple variants with differences in either charge, molecular weight or other properties is a common feature of monoclonal antibodies. These charge variants are generally referred to as acidic or basic compared with the main species. The chemical nature of the main species is usually well-understood, but understanding the chemical nature of acidic and basic species, and the differences between all three species, is critical for process development and formulation design. Complete understanding of acidic and basic species, however, is challenging because both species are known to contain multiple modifications, and it is likely that more modifications may be discovered. This review focuses on the current understanding of the modifications that can result in the generation of acidic and basic species and their affect on antibody structure, stability and biological functions. Chromatography elution profiles and several critical aspects regarding fraction collection and sample preparations necessary for detailed characterization are also discussed.
Collapse
Affiliation(s)
- Yi Du
- Merck Research Laboratories, Union, NJ, USA
| | | | | | | | | | | |
Collapse
|
99
|
Eon-Duval A, Broly H, Gleixner R. Quality attributes of recombinant therapeutic proteins: An assessment of impact on safety and efficacy as part of a quality by design development approach. Biotechnol Prog 2012; 28:608-22. [DOI: 10.1002/btpr.1548] [Citation(s) in RCA: 142] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2012] [Revised: 03/26/2012] [Indexed: 12/12/2022]
|
100
|
Luo J, Zhang J, Ren D, Tsai WL, Li F, Amanullah A, Hudson T. Probing of C-terminal lysine variation in a recombinant monoclonal antibody production using Chinese hamster ovary cells with chemically defined media. Biotechnol Bioeng 2012; 109:2306-15. [DOI: 10.1002/bit.24510] [Citation(s) in RCA: 63] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2011] [Revised: 03/08/2012] [Accepted: 03/19/2012] [Indexed: 12/18/2022]
|